Background
Massive perivillous fibrin deposition (MPVFD) is a potentially
devastating pregnancy complication that occurs in 0.03-0.5% of
deliveries and is associated with severe fetal growth restriction,
stillbirth (IUFD), and neurologic injury due to uteroplacental
insufficiency1,2. Management of patients with
recurrent pregnancy loss secondary to MPVFD has not been widely studied.